Abstract
Pregabalin has a multidimensional effect across a range of disorders that have of a pathogenesis involving a CNS response of abnormal hyperexcitability. The high-affinity binding of pregabalin at α2δ proteins and the subsequent reduction in excessive release of several excitatory neurotransmitters appears to be responsible for the clinical benefits of pregabalin in treating fibromyalgia, neurological pain and generalized anxiety disorder. The use of pregabalin in these complex and difficult-to-treat conditions is associated with rapid and durable clinically significant improvements in several outcome measures relating to core symptoms, including pain, anxiety and sleep, and improvements in overall health status and health-related quality-of-life. The most common adverse events associated with the drug are dizziness and somnolence, which are generally mild to moderate in intensity and are tolerated by many patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
